Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer

详细信息    查看全文

• 作者：Aneta Zysk^a ; Mark O. DeNichilo^a ; Vasilios Panagopoulos^a ; Irene Zinonos^a ; Vasilios Liapis^a ; Shelley Hay^a ; Wendy Ingman^b ; Vladimir Ponomarev^c ; Gerald Atkins^d ; David Findlay^d ; Andrew Zannettino^e ; Andreas Evdokiou^a ; ^{andreas.evdokiou@adelaide.edu.au}
• 关键词：Metastasis ; Immunotherapy ; Bisphosphonate ; Osteoclast ; Tumour associated macrophage
• 刊名：Cancer Letters
• 出版年：2017
• 出版时间：1 February 2017
• 年：2017
• 卷：386
• 期：Complete
• 页码：141-150
• 全文大小：1733 K
• 卷排序：386

文摘

Immunotherapy using cytotoxic Vγ9Vδ2 T cells is gaining momentum as a novel therapeutic approach for the treatment of solid and haematological malignancies. Vγ9Vδ2 T cells localise to breast cancer lesions in the bone and multiple Vγ9Vδ2 T cell infusions decrease tumour burden and lung metastases. ZOL pre-treatment potentiates the anti-cancer efficacy of Vγ9Vδ2 T cells and decreases tumour-associated bone loss. Adoptive transfer of Vγ9Vδ2 T cells in combination with ZOL may be beneficial in patients with advanced breast cancer.